| Clinical pharmacokinetics and pharmacodynamics of micafungin RE Wasmann, EW Muilwijk, DM Burger, PE Verweij, CA Knibbe, ... Clinical pharmacokinetics 57, 267-286, 2018 | 80 | 2018 |
| Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals C Smit, RE Wasmann, SC Goulooze, MJ Wiezer, EPA van Dongen, ... British journal of clinical pharmacology 86 (2), 303-317, 2020 | 43 | 2020 |
| Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs JB Buil, RJM Brüggemann, RE Wasmann, J Zoll, JF Meis, WJG Melchers, ... Journal of Antimicrobial Chemotherapy 73 (1), 134-142, 2018 | 34 | 2018 |
| Pharmacokinetics of anidulafungin in obese and normal-weight adults RE Wasmann, R Ter Heine, EP van Dongen, DM Burger, VJ Lempers, ... Antimicrobial agents and chemotherapy 62 (7), 10.1128/aac. 00063-18, 2018 | 30 | 2018 |
| Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing EW Muilwijk, DW de Lange, JA Schouten, RE Wasmann, R Ter Heine, ... Antimicrobial Agents and Chemotherapy 64 (10), 10.1128/aac. 00984-20, 2020 | 26 | 2020 |
| Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults RE Wasmann, C Smit, R Ter Heine, SE Koele, EPH van Dongen, ... Journal of Antimicrobial Chemotherapy 74 (4), 978-985, 2019 | 24 | 2019 |
| Implications for IV posaconazole dosing in the era of obesity RE Wasmann, C Smit, MH van Donselaar, EPA van Dongen, RMJ Wiezer, ... Journal of Antimicrobial Chemotherapy 75 (4), 1006-1013, 2020 | 23 | 2020 |
| Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study P Denti, RE Wasmann, A Van Rie, J Winckler, A Bekker, H Rabie, ... Clinical Infectious Diseases 75 (1), 141-151, 2022 | 22 | 2022 |
| Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis F Gafar, RE Wasmann, HM McIlleron, RE Aarnoutse, HS Schaaf, ... European Respiratory Journal 61 (3), 2023 | 18 | 2023 |
| Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children RE Wasmann, EM Svensson, AS Walker, MN Clements, P Denti British Journal of Clinical Pharmacology 87 (7), 2847-2854, 2021 | 18 | 2021 |
| Extrahepatic metabolism of ibrutinib JJM Rood, A Jamalpoor, S van Hoppe, MJ van Haren, RE Wasmann, ... Investigational New Drugs 39 (1), 1-14, 2021 | 17 | 2021 |
| Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study C Smit, RE Wasmann, MJ Wiezer, H van Dongen, JW Mouton, ... PHARMACEUTICAL RESEARCH 37 (2), 2020 | 17 | 2020 |
| Fixed dosing of liposomal amphotericin B in morbidly obese individuals RE Wasmann, C Smit, EPH van Dongen, RMJ Wiezer, J Adler-Moore, ... Clinical Infectious Diseases 70 (10), 2213-2215, 2020 | 16 | 2020 |
| Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy R Griesel, AN Kawuma, R Wasmann, S Sokhela, G Akpomiemie, ... British journal of clinical pharmacology, 2021 | 15 | 2021 |
| A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin: towards individualized dosing in obese patients C Smit, RE Wasmann, SC Goulooze, EJ Hazebroek, EPA Van Dongen, ... Clinical Pharmacokinetics 58, 1333-1343, 2019 | 15 | 2019 |
| One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation P Denti, RE Wasmann, J Francis, H McIlleron, N Sugandhi, TR Cressey, ... The Lancet Child & Adolescent Health 6 (1), 9-10, 2022 | 12 | 2022 |
| Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non-obese individuals: a prospective clinical study KP van Rhee, C Smit, RE Wasmann, PD van der Linden, R Wiezer, ... Clinical Pharmacokinetics 61 (8), 1167-1175, 2022 | 10 | 2022 |
| Population pharmacokinetic model and alternative dosing regimens for dolutegravir coadministered with rifampicin AN Kawuma, RE Wasmann, KE Dooley, M Boffito, G Maartens, P Denti Antimicrobial agents and chemotherapy 66 (6), e00215-22, 2022 | 7 | 2022 |
| Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model AN Kawuma, RE Wasmann, KE Dooley, G Maartens, P Denti British journal of clinical pharmacology 89 (3), 1216-1221, 2023 | 6 | 2023 |
| Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine AN Kawuma, SI Walimbwa, G Pillai, S Khoo, M Lamorde, RE Wasmann, ... Journal of Antimicrobial Chemotherapy 76 (5), 1269-1272, 2021 | 5 | 2021 |
Roger BruggemannVerified email at radboudumc.nl
